+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Age: 18Years +All GendersPhase 3
28 locations
A

Actively Recruiting

Researchers are evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 compared to a reference drug in adults with relapsing-remitting multiple sclerosis RRMS. This phase 3 study focuses on patients diagnosed according to the 2017 McDonald criteria, aiming to better understand how BCD-281 performs in managing RRMS symptoms and disease activity. Participants are randomly assigned to receive either BCD-281 or the reference drug Ocrelizumab, both anti-CD20 monoclonal antibodies. The dosing starts with 300 mg for the first two infusions, followed by 600 mg for subsequent infusions. The study includes a screening period of up to 28 days, a double-blind treatment phase lasting 72 weeks, an open-label phase from weeks 72 to 96, and a follow-up period from weeks 96 to 100. During the study, participants will undergo regular assessments including MRI scans to measure lesions, neurological exams using the Expanded Disability Status Scale, and performance tests like the Timed 25-Foot Walk and 9-Hole Peg Test. Quality of life is also evaluated through questionnaires. Researchers will monitor adverse reactions, antibody development, and pharmacokinetic markers throughout the 100-week period to comprehensively assess the treatments effects and safety.

Age: 18Years - 55YearsAll GendersPhase 3
1 location
W

Actively Recruiting

Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.

Age: 10Years - 17YearsAll GendersPhase 3
81 locations
C

Actively Recruiting

Researchers are evaluating the investigational drug GNR-139 compared to the reference drug Eylea in patients with neovascular age-related macular degeneration nAMD who have not received prior treatment. This multicenter, randomized, double-blind study aims to assess whether GNR-139 has similar effectiveness and safety as Eylea by measuring changes in visual acuity. Participants will be randomly assigned in a 21 ratio to receive either GNR-139 or Eylea, both administered as an 8 mg intravitreal injection. The study includes two groups 120 patients receiving GNR-139 and 60 patients receiving Eylea. Treatments are given by injection into the eye, and neither participants nor doctors know which drug is given. Throughout the study, participants will have their visual acuity measured using the ETDRS chart at multiple time points up to Week 56. Optical coherence tomography OCT and fluorescein angiography FFA will assess retinal changes and lesion areas. Researchers will monitor safety, immunogenicity, and treatment effects over one year, including tracking the number of injections and any adjustments needed in treatment intervals.

Age: 50Years +All GendersPhase 3
14 locations
O

Actively Recruiting

Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.

Age: 18Years +MALE
28 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.

Age: 18Years - 74YearsFEMALEPhase 2
47 locations
O

Actively Recruiting

Researchers are studying adult patients with Neurofibromatosis type 1 NF1 in Russia to evaluate clinical and patient-reported outcomes in routine care settings. This observational, open-label, single-arm, multi-center cohort study focuses on adults diagnosed with NF1 and associated plexiform neurofibromas PN. Participants are adults aged 18 years or older with confirmed NF1 and PN diagnosis verified by clinical assessment, ultrasound imaging, MRI, or biopsy. The study includes patients with existing PN-associated symptoms who are either newly diagnosed or have PN without prior MEK-inhibitor therapy. No investigational drugs are given, as this is a non-interventional study observing routine care. During the study, participants provide data at their initial visit, including demographics, clinical history, PN characteristics, comorbidities, disability degree, and prior examinations. Researchers collect information on hospitalizations and disease progression over time. The primary outcomes include age at inclusion and diagnosis, body measurements, symptom duration, and disability changes. Participants are followed according to routine care until study completion in 2028.

All AgesAll Genders
16 locations
O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
P

Actively Recruiting

Researchers are evaluating Raphamin in adults aged 18 to 64 years who have acute bronchitis symptoms lasting less than 72 hours. This randomized, double-blind, placebo-controlled phase 3 trial aims to determine if Raphamin can speed up symptom resolution, reduce disease severity, and prevent complications requiring antibiotics compared to placebo. The study includes both men and women during the seasonal period of acute respiratory viral infections. Participants are randomly assigned to receive either Raphamin or a placebo following a specific oral dosing schedule for 5 days. On the first day, participants take 8 tablets of Raphamin or placebo one tablet every 30 minutes for the first 2 hours total of 5 tablets, then one tablet three times spaced evenly throughout the day. From day 2 onwards, one tablet is taken three times daily. The study uses an electronic patient diary to record daily symptoms, and face-to-face visits are scheduled on days 1, 4, and 7, with a phone visit on day 14. Throughout the study, participants undergo physical exams, vital sign monitoring, pulse oximetry, and laboratory tests including blood counts and PCR for respiratory viruses. Symptom severity is assessed by the Bronchitis Severity Scale and the Integrative Medicine Outcome Scale. Quality of life is evaluated using the EQ-5D instrument. Safety is monitored through recording adverse events and any use of antibacterial medications or hospitalizations. The total duration of participation includes treatment and follow-up over 14 days.

Age: 18Years - 64YearsAll GendersPhase 3
33 locations
R

Actively Recruiting

Researchers are studying treatment options for patients with gastric cancer that has spread to the peritoneum, known as peritoneal carcinomatosis. This randomized phase 2 trial compares the safety and effectiveness of standard polychemotherapy using the FLOT regimen with a combination of polychemotherapy and pressurized intraperitoneal aerosol chemotherapy PIPAC sessions. The goal is to evaluate whether adding PIPAC improves outcomes such as progression-free survival and complications from treatment. Participants are divided into two groups after initial diagnostic laparoscopy. The control group receives six courses of polychemotherapy using the FLOT scheme, with evaluations after the 3rd and 6th courses including repeat diagnostic laparoscopy. The study group receives six courses alternating between FLOT and modified FLOT mFLOT regimens, combined with PIPAC sessions using docetaxel during the 2nd, 4th, and 6th courses. Instead of repeat laparoscopy, this group has revisions during the PIPAC sessions. Treatment response is monitored by the Peritoneal Regression Grading Score PRGS. During the study, participants undergo regular examinations, biopsies, peritoneal lavage for cytology, and assessments of tumor spread. The study monitors progression-free survival over four and a half years and complications from chemotherapy over three and a half years. Secondary outcomes include overall survival, quality of life, surgical complications, and the completeness of planned therapy. Patients may be observed or considered for cytoreductive surgery based on their response, with second-line chemotherapy or palliative care options if needed. The total study duration allows for ongoing monitoring and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
1 location

1-10 of 25

1